FI935471A - Pysyvästi vapauttava valmiste - Google Patents

Pysyvästi vapauttava valmiste Download PDF

Info

Publication number
FI935471A
FI935471A FI935471A FI935471A FI935471A FI 935471 A FI935471 A FI 935471A FI 935471 A FI935471 A FI 935471A FI 935471 A FI935471 A FI 935471A FI 935471 A FI935471 A FI 935471A
Authority
FI
Finland
Prior art keywords
group
formula
sustained
amino
chem
Prior art date
Application number
FI935471A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI935471A0 (fi
Inventor
Shigeru Kamei
Yasutaka Igari
Yasuaki Ogawa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of FI935471A0 publication Critical patent/FI935471A0/fi
Publication of FI935471A publication Critical patent/FI935471A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI935471A 1992-12-07 1993-12-07 Pysyvästi vapauttava valmiste FI935471A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP32707092 1992-12-07
JP1897893 1993-02-05
JP14513493 1993-06-16

Publications (2)

Publication Number Publication Date
FI935471A0 FI935471A0 (fi) 1993-12-07
FI935471A true FI935471A (fi) 1994-06-08

Family

ID=27282444

Family Applications (2)

Application Number Title Priority Date Filing Date
FI935471A FI935471A (fi) 1992-12-07 1993-12-07 Pysyvästi vapauttava valmiste
FI20030166A FI116196B (fi) 1992-12-07 2003-02-04 Menetelmä jatkuvasti vapauttavan valmisteen tuottamiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20030166A FI116196B (fi) 1992-12-07 2003-02-04 Menetelmä jatkuvasti vapauttavan valmisteen tuottamiseksi

Country Status (24)

Country Link
US (7) US5480868A (fr)
EP (2) EP0601799B1 (fr)
JP (1) JP3725906B2 (fr)
KR (2) KR100305951B1 (fr)
CN (2) CN1099893C (fr)
AT (2) ATE203910T1 (fr)
AU (1) AU669939B2 (fr)
CA (1) CA2110730C (fr)
DE (2) DE69333817T2 (fr)
DK (2) DK1088555T3 (fr)
EE (1) EE03117B1 (fr)
ES (2) ES2158856T3 (fr)
FI (2) FI935471A (fr)
GE (1) GEP19991600B (fr)
GR (1) GR3037085T3 (fr)
HK (1) HK1037519A1 (fr)
LV (1) LV10927B (fr)
MX (1) MX9307686A (fr)
NO (1) NO310704B1 (fr)
NZ (1) NZ250349A (fr)
PT (2) PT1088555E (fr)
SG (1) SG46283A1 (fr)
TW (1) TW333456B (fr)
WO (1) WO1994013317A1 (fr)

Families Citing this family (326)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
EP0647449A1 (fr) * 1993-06-24 1995-04-12 Takeda Chemical Industries, Ltd. Préparation libérant continuellement une substance anti-endotheline
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
WO1996022786A1 (fr) * 1995-01-23 1996-08-01 Takeda Chemical Industries, Ltd. Preparation a diffusion prolongee et son emploi
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
TW448055B (en) * 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
DK0839525T3 (da) 1996-10-31 2004-11-29 Takeda Pharmaceutical Præparat med forlænget frigivelse
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
CA2355186C (fr) * 1998-12-15 2008-03-18 Takeda Chemical Industries, Ltd. Procede de production d'un polymere
AU4390200A (en) * 1999-02-19 2000-09-04 Bioserv Ag Biodegradable composite material for the production of microcapsules
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US20040023987A1 (en) * 2000-06-14 2004-02-05 Yoshio Hata Sustained release compositions
WO2002002144A1 (fr) 2000-07-05 2002-01-10 Takeda Chemical Industries, Ltd. Preparations medicinales pour le traitement des maladies dependant des hormones sexuelles
JP5046447B2 (ja) * 2000-08-07 2012-10-10 和光純薬工業株式会社 乳酸重合体及びその製造方法
WO2002043709A1 (fr) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
WO2002058672A2 (fr) * 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticules de polymere biodegradable encapsulant une substance biologiquement active et formulations pharmaceutiques a liberation prolongee contenant lesdites particules
WO2002058671A1 (fr) * 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticules pharmaceutiques exemptes d"eclatement
CA2451187C (fr) * 2001-06-22 2012-08-14 Southern Biosystems, Inc. Implants coaxiaux a liberation prolongee d'ordre 0
TWI225416B (en) 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
EP1443907A1 (fr) 2001-11-12 2004-08-11 Alkermes Controlled Therapeutics, Inc. Melanges de polymeres biocompatibles et leur utilisation
US7812044B2 (en) 2001-11-13 2010-10-12 Takeda Pharmaceutical Company Limited Anticancer agents
CA2472956A1 (fr) * 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Strategies de formulation dans la stabilisation de peptides dans des solvants organiques et a l'etat seche
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1866319B1 (fr) 2005-04-01 2011-11-23 The Regents of The University of California Nucleosides phosphono-pent-2-en-1-yle et analogues
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
EP1716847B1 (fr) * 2005-04-28 2008-01-02 Nipro Corporation Composition pharmaceutique bioabsorbable contenant un copolymère de PLGA
DK3081215T3 (da) 2005-05-23 2020-04-27 Natural Alternatives Int Inc Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin
KR20080028981A (ko) * 2005-06-30 2008-04-02 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Ｇｌｐ-1 약학 조성물
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
EP3363455A1 (fr) 2005-12-30 2018-08-22 Zensun (Shanghai) Science & Technology, Co., Ltd. Libération prolongée de la neuréguline destinée à améliorer la fonction cardiaque
JP2009530280A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド シタクスセンタンナトリウムの配合物
JP2009530284A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド 拡張期心不全を治療するための方法と組成物
PL2383271T3 (pl) * 2006-03-13 2013-12-31 Kyorin Seiyaku Kk Aminochinolony jako inhibitory GSK-3
US8323676B2 (en) * 2008-06-30 2012-12-04 Abbott Cardiovascular Systems Inc. Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug
US20090258028A1 (en) * 2006-06-05 2009-10-15 Abbott Cardiovascular Systems Inc. Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
EP2066662B1 (fr) 2006-09-21 2012-12-05 Kyorin Pharmaceutical Co., Ltd. Inhibiteurs de serine hydrolase
AU2007310949A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
WO2008057604A2 (fr) * 2006-11-08 2008-05-15 The Regents Of The University Of California Agents thérapeutiques contenant de petites molécules, synthèses d'analogues et de dérivés et leurs procédés d'utilisation
CA2670976C (fr) 2006-11-30 2015-01-27 Atsushi Hasuoka Compose amine cyclique
TWI481424B (zh) 2006-12-18 2015-04-21 Takeda Pharmaceutical 緩釋性組成物及其製法
WO2008106167A1 (fr) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Polythérapie incluant des inhibiteurs de métalloprotéinases matricielles et des inhibiteurs de caspases pour le traitement de maladies hépatiques
EP2144604B1 (fr) 2007-02-28 2011-09-21 Conatus Pharmaceuticals, Inc. Procédés pour le traitement d'hépatite C virale chronique en utilisant RO 113-0830
US20080220104A1 (en) * 2007-03-08 2008-09-11 Cappello John V Compositions for producing satiety
TW200846305A (en) 2007-03-15 2008-12-01 Auspex Pharmaceuticals Inc Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
EP2139447A2 (fr) 2007-03-20 2010-01-06 Harold Brem Compositions gm-csf cosméceuticales et leurs procédés d'utilisation
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
CN101801188A (zh) * 2007-07-12 2010-08-11 特拉加拉医药品公司 治疗癌症、肿瘤和肿瘤相关性疾病的方法和组合物
ITSA20070024A1 (it) * 2007-07-27 2009-01-28 Univ Degli Studi Salerno Processo continuo per la produzione di microsfere mediante liquidi espansi.
MX2010002667A (es) * 2007-09-11 2010-04-01 Activx Biosciences Inc Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
BRPI0816814B1 (pt) 2007-09-12 2021-08-31 Kyorin Pharmaceutical Co. Ltd Composto, composição farmacêutica e uso de um composto
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
US8618289B2 (en) 2008-03-17 2013-12-31 Ambit Biosciences Corporation RAF kinase modulator compounds and methods of use thereof
WO2009139880A1 (fr) * 2008-05-13 2009-11-19 Celgene Corporation Composés et compositions de thioxo-isoindoline, et procédés d'utilisation
BRPI0912842A8 (pt) * 2008-05-20 2019-01-29 Cerenis Therapeutics Holding composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
US8765162B2 (en) 2008-06-30 2014-07-01 Abbott Cardiovascular Systems Inc. Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
ES2458358T3 (es) 2008-07-02 2014-05-05 Idenix Pharmaceuticals, Inc. Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas
CN104248623B (zh) * 2008-09-04 2020-04-03 安米林药品有限责任公司 使用非水性载体的持续释放制剂
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
WO2010088450A2 (fr) 2009-01-30 2010-08-05 Celladon Corporation Procédés de traitement de maladies associées à la modulation de serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
CN102395576A (zh) * 2009-02-27 2012-03-28 埃姆比特生物科学公司 调控jak激酶的喹唑啉衍生物和其使用方法
US8193372B2 (en) 2009-03-04 2012-06-05 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole HCV polymerase inhibitors
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
AU2010221990B2 (en) * 2009-03-11 2015-06-04 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as GSK-3 inhibitors
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010110686A1 (fr) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl et 1,3,5-triazinyl benzimidazoles et leur utilisation en thérapie anticancéreuse
CN102459210B (zh) 2009-04-22 2015-09-02 埃克希金医药品有限公司 芳基磺酰胺ccr3拮抗剂
NZ595797A (en) 2009-04-22 2014-03-28 Axikin Pharmaceuticals Inc 2,5-disubstituted arylsulfonamide ccr3 antagonists
BRPI1014669A2 (pt) 2009-04-22 2017-07-18 Axikin Pharmaceuticals Inc antagonistas ccr3 de arilsulfonamida 2,5-dissubstituída
US8911766B2 (en) * 2009-06-26 2014-12-16 Abbott Cardiovascular Systems Inc. Drug delivery compositions including nanoshells for triggered drug release
WO2011003870A2 (fr) 2009-07-06 2011-01-13 Creabilis S.A. Corticostéroïdes mini-pegylés, compositions les comprenant et procédés pour les préparer et les utiliser
EP3072890B1 (fr) 2009-07-07 2018-10-17 MEI Pharma, Inc. Pyrimidinyl et 1,3,5-triazinyl benzimidazoles et leur utilisation dans la thérapie du cancer
HUE035519T2 (en) 2009-07-08 2018-05-02 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical composition
EP2467144A1 (fr) 2009-07-24 2012-06-27 ViroLogik GmbH Association d'inhibiteurs du protéasome et de médicaments anti-hépatite dans le traitement de l'hépatite
WO2011017389A1 (fr) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la sérine protéase macrocyclique utiles contre les infections virales, en particulier le virus de l’hépatite c
CA2770454A1 (fr) 2009-08-19 2011-02-24 Ambit Biosciences Corporation Composes biaryles et procedes d'utilisation de ceux-ci
KR102148624B1 (ko) 2009-09-28 2020-08-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
WO2011056566A2 (fr) 2009-10-26 2011-05-12 Sunesis Pharmaceuticals, Inc. Composés et procédés pour traitement de cancer
WO2011056764A1 (fr) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Imidazo[2,1-b][1,3]benzothiazoles enrichis en isotopes ou fluores
WO2011064769A1 (fr) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Procédés et compositions pharmaceutiques pour le traitement des bouffées de chaleur
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
CA2784748A1 (fr) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. Inhibiteurs du virus de l'hepatite c a base de 5,5-arylene ou heteroarylene condense
IN2012DN04858A (fr) * 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
US20120010131A1 (en) 2009-12-30 2012-01-12 Scynexis, Inc. Novel cyclosporin analogues
WO2011089166A1 (fr) 2010-01-19 2011-07-28 Virologik Gmbh Inhibiteurs du protéasome à base de semicarbazone pour traiter une infection par le vih et une infection par une hépatite
WO2011094890A1 (fr) 2010-02-02 2011-08-11 Argusina Inc. Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
WO2011097525A1 (fr) 2010-02-05 2011-08-11 Tragara Pharmaceuticals, Inc. Formes à l'état solide d'inhibiteurs macrocycliques de kinases
EP4289838A3 (fr) 2010-02-11 2024-03-13 Celgene Corporation Dérivés d'arylméthoxy isoindoline substitués, compositions les comportant et procédés d'utilisation associés
HUE025699T2 (en) 2010-03-02 2016-04-28 Axikin Pharmaceuticals Inc Isotopically enriched arylsulfonamide derivatives as CCR3 antagonists
WO2011112689A2 (fr) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Sels d'indazolylpyrrolotriazine
MX336559B (es) 2010-03-17 2016-01-25 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida.
US9296722B2 (en) 2010-05-27 2016-03-29 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011150201A2 (fr) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Composés azolylamide et leurs procédés d'utilisation
CA2801001A1 (fr) 2010-06-01 2011-12-08 Biotheryx, Inc. Derives d'hydroxypyridone, compositions pharmaceutiques realisees a partir de ces derives, et utilisations therapeutiques correspondants pour traiter des maladies proliferatives
WO2011153199A1 (fr) 2010-06-01 2011-12-08 Biotheryx, Inc. Méthodes permettant de traiter des tumeurs malignes hématologiques au moyen de 6-cyclohexyl-1-hydroxy-4-méthyl-2(1h)-pyridone
CA2801778C (fr) 2010-06-07 2018-06-05 Novomedix, Llc Composes furanyliques et leur utilisation
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
US20130178522A1 (en) 2010-07-19 2013-07-11 James M. Jamison Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
US8633207B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
US20130303533A1 (en) 2010-09-01 2013-11-14 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
EP2611794A1 (fr) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Dérivés de 4-azolylaminoquinazoline et leurs méthodes d'utilisation
EP2611448A1 (fr) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Dérivés de 7-cyclylquinazoline et leurs méthodes d'utilisation
WO2012030944A2 (fr) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Composés quinoléine et isoquinoléine et leurs procédés d'utilisation
WO2012030910A1 (fr) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Dérivés de 2-cycloquinazoline et leurs méthodes d'utilisation
EP2611812A1 (fr) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Composés thiénopyridines et thiénopyrimidines et leurs procédés d'utilisation
JP5932794B2 (ja) 2010-09-01 2016-06-08 アムビト ビオスシエンセス コルポラチオン 光学活性のあるピラゾリルアミノキナゾリン及びその医薬組成物及び使用方法
EP2611502A1 (fr) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Composés de modulation du récepteur a3 de l'adénosine et leurs méthodes d'utilisation
CA2809983A1 (fr) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Sels bromhydrates d'une pyrazolylaminoquinazoline
WO2012044641A1 (fr) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinylbenzimidazolsulfonamides et leur utilisation en thérapie anticancéreuse
WO2012051090A1 (fr) 2010-10-11 2012-04-19 Axikin Pharmaceuticals, Inc. Sels d'antagonistes arylsulfonamide de ccr3
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2648676A4 (fr) 2010-12-06 2016-05-04 Follica Inc Procédés destinés à traiter la calvitie et à favoriser la croissance des cheveux
WO2012080050A1 (fr) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Formes solides d'un composé de phénoxybenzènesulfonyle
KR101411349B1 (ko) 2010-12-24 2014-06-25 주식회사 삼양바이오팜 생리활성 펩타이드를 포함하는 마이크로입자 및 그의 제조방법, 및 그를 포함하는 약제학적 조성물
BR112013017670B1 (pt) 2011-01-10 2022-07-19 Infinity Pharmaceuticals, Inc Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas
CN103338753A (zh) 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
HUE027481T2 (en) 2011-03-11 2016-09-28 Celgene Corp Methods of treating cancer with 3- (5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl) -piperidine-2,6-dione
AU2012236722A1 (en) 2011-03-28 2013-10-17 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
TWI572599B (zh) 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
US20140088103A1 (en) 2011-03-28 2014-03-27 Mei Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2691409B1 (fr) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Composés et compositions pharmaceutiques pour le traitement d'infections virales
MX2013015373A (es) 2011-06-23 2014-02-11 Map Pharmaceuticals Inc Nuevos analogos de fluoroergolina.
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
WO2013012915A1 (fr) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Composés hétérocycliques et leurs utilisations
CA2846431A1 (fr) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Composes heterocycliques et leurs utilisations
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
JP6162130B2 (ja) 2011-10-14 2017-07-12 アムビト ビオスシエンセス コルポラチオン Ｉｉｉ型受容体チロシンキナーゼの調節因子としての複素環式化合物及びその使用
CA2859173A1 (fr) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Nouveaux derives d'iso-ergoline
US8946420B2 (en) 2011-12-21 2015-02-03 Map Pharmaceuticals, Inc. Neuromodulatory compounds
WO2013130600A1 (fr) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Formes solides comprenant de la pyrazolylaminoquinazoline optiquement active, compositions à base de celles-ci et leurs utilisations
SG10201507714XA (en) 2012-03-16 2015-10-29 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2852603B1 (fr) 2012-05-22 2021-05-12 Idenix Pharmaceuticals LLC Composés d'acide d-aminé contre les maladies hépatiques
WO2013177195A1 (fr) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. Promédicaments de 3',5'-phosphate cyclique pour traiter une infection par le virus de l'hépatite c
WO2013177188A1 (fr) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
JP6246712B2 (ja) 2012-07-12 2017-12-13 武田薬品工業株式会社 マイクロカプセル粉末の製造方法
AU2013299631B2 (en) 2012-08-09 2017-09-28 Celgene Corporation Salts and solid forms of (S)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
PL2882441T3 (pl) 2012-08-09 2020-09-21 Celgene Corporation Leczenie chorób immunologicznych i zapalnych
CA2922849A1 (fr) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents utiles pour le traitement de l'obesite, du diabete et de troubles associes
CN104781240A (zh) 2012-09-07 2015-07-15 埃克希金医药品有限公司 同位素富集的芳基磺酰胺ccr3拮抗剂
WO2014055647A1 (fr) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl et sulfonyl benzimidazolyl) pyrimidines et triazines, compositions pharmaceutiques les contenant, et leur utilisation pour traiter les maladies prolifératives
CN111848711A (zh) 2012-10-08 2020-10-30 埃迪尼克斯医药有限责任公司 用于hcv感染的2′-氯核苷类似物
WO2014063019A1 (fr) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Composés dinucléotides contre une infection par le vhc
WO2014066239A1 (fr) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. Nucléosides 2', 4'-pontés pour l'infection par le vhc
TR201812261T4 (tr) 2012-11-01 2018-11-21 Infinity Pharmaceuticals Inc Pi3 ki̇naz i̇zoform modülatörleri̇ i̇le kanser tedavi̇si̇
EP2916830A2 (fr) 2012-11-08 2015-09-16 Summa Health System Vitamine c, vitamine k, un polyphénol et leurs combinaisons pour la cicatrisation des plaies
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
WO2014078436A1 (fr) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. Ester de d-alanine d'analogue de sp-nucléoside
MX370519B (es) 2012-11-30 2019-12-17 Novomedix Llc Sulfonamidas con sustitucion biarilo y su uso.
WO2014099941A1 (fr) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro-nucléosides pour le traitement du vhc
US8895743B2 (en) 2012-12-21 2014-11-25 Map Pharmaceuticals, Inc. Methysergide derivatives
WO2014110305A1 (fr) 2013-01-11 2014-07-17 Mayo Foundation For Medical Education And Research Vitamines c et k pour le traitement de maladies polykystiques
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014165542A1 (fr) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoronucléosides pour le traitement du vhc
SG11201509842SA (en) 2013-05-30 2015-12-30 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
WO2014197578A1 (fr) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucléosides pour le traitement du virus de l'hépatite c (vhc)
WO2015017713A1 (fr) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. Pronucléotides phosphoramidates avec acides aminés d de composés halogéno pyrimidines pour le traitement des hépatopathies
CN105683182A (zh) 2013-08-30 2016-06-15 埃姆比特生物科学公司 联芳基乙酰胺化合物及其使用方法
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (fr) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
MY175778A (en) 2013-10-04 2020-07-08 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061683A1 (fr) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. Pronucléotides thiophosphoramidates à acide aminé d et pronucléotides thiophosphoramidates à d-analine de composés de nucléoside utiles pour le traitement du vhc
CN104587534A (zh) * 2013-10-31 2015-05-06 先健科技(深圳)有限公司 可吸收铁基合金支架
EP3063165A1 (fr) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC Pronucléotides phosphoramidates de d-alanine de composés de nucléoside 2'-méthyl 2'-fluoro guanosine dans le traitement du vhc
JP2017504572A (ja) 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
EP3074399A1 (fr) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC Analogues de nucléoside 2'-dichloro et 2'-fluoro-2'-chloro analogues pour l'infection par le vhc
EP3083654A1 (fr) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC Nucléosides 4'-or pour le traitement du vhc
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
PT3119762T (pt) 2014-03-20 2021-08-31 Capella Therapeutics Inc Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro
WO2015143161A1 (fr) 2014-03-20 2015-09-24 Capella Therapeutics, Inc. Dérivés de benzimidazole en tant qu'inhibiteurs de la tyrosine kinase erbb pour le traitement du cancer
US10106549B2 (en) 2014-04-09 2018-10-23 Siteone Therapeutics, Inc. 10′,11′-modified saxitoxins useful for the treatment of pain
WO2015161137A1 (fr) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. Nucléosides méthyle ou alcynyle substitués en position 3 pour le traitement du virus de l'hépatite c
US9956164B2 (en) 2014-04-16 2018-05-01 Veyx-Pharma Gmbh Veterinary pharmaceutical composition and use thereof
WO2015168079A1 (fr) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k
KR20170015312A (ko) 2014-05-12 2017-02-08 코나터스 파마슈티칼스, 인크. 카스파제 억제제를 사용한 만성 간질환의 합병증의 치료
CA2947939A1 (fr) 2014-05-28 2015-12-03 Idenix Pharmaceuticals Llc Derives de nucleosides pour le traitement du cancer
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
AU2015277786B2 (en) 2014-06-19 2019-04-18 Takeda Pharmaceutical Company Limited Heteroaryl compounds for kinase inhibition
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
US20170319548A1 (en) 2014-09-12 2017-11-09 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016054491A1 (fr) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
CA2965169C (fr) 2014-10-21 2021-11-16 Ariad Pharmaceuticals, Inc. Formes cristallines de 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine
EP3209658A1 (fr) 2014-10-24 2017-08-30 Biogen MA Inc. Dérivés de diterpénoïdes et leurs procédés d'utilisation
CN107250116B (zh) 2014-12-23 2020-10-27 艾士盟医疗公司 3,5-二氨基吡唑激酶抑制剂
EP3253753A4 (fr) 2015-01-20 2018-06-27 Xoc Pharmaceuticals, Inc Composés d'ergoline et leurs utilisations
AU2016209490B2 (en) 2015-01-20 2020-09-03 Xoc Pharmaceuticals, Inc. Isoergoline compounds and uses thereof
CN108368147A (zh) 2015-05-27 2018-08-03 南方研究院 用于治疗癌症的核苷酸
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
US20190015396A1 (en) 2015-06-23 2019-01-17 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
PT3640345T (pt) 2015-08-17 2021-12-29 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
AU2016329201A1 (en) 2015-09-30 2018-04-26 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
HUE065406T2 (hu) 2015-10-30 2024-05-28 Neurocrine Biosciences Inc Valbenazin-dihidroklorid sók és polimorfjaik
WO2017079566A1 (fr) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Inhibiteurs de caspase destinés à être utilisés dans le traitement du cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
WO2017117478A1 (fr) 2015-12-31 2017-07-06 Conatus Pharmaceuticals Inc. Méthodes d'utilisation d'inhibiteurs de caspase dans le traitement d'une hépatopathie
TWI733734B (zh) 2016-01-08 2021-07-21 美商西建公司 2-(4-氯苯基)-n-((2-(2,6-二氧六氫吡啶-3-基)-1-氧基異吲哚啉-5-基)甲基)-2,2-二氟乙醯胺之固體型式，及其醫藥組合物及用途
MX367669B (es) 2016-01-08 2019-08-30 Celgene Corp Compuestos antiproliferativos y sus composiciones farmacéuticas y usos.
US10648983B2 (en) 2016-01-08 2020-05-12 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
CA3020681A1 (fr) 2016-04-11 2017-10-19 Clexio Biosciences Ltd. Derives de ketamine deuteres
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
EP3448851B8 (fr) 2016-04-29 2022-04-27 FGH BioTech, Inc. Composés de pyrazole di-substitués pour le traitement de maladies
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3036195A1 (fr) 2016-09-07 2018-03-15 Fgh Biotech, Inc. Composes de pyrazole di-substitues pour le traitement de maladies
KR20190058550A (ko) 2016-09-19 2019-05-29 메이 파마, 아이엔씨. 병용 요법
DK3534885T3 (da) 2016-11-03 2021-04-12 Kura Oncology Inc Farnesyltransferase-inhibitorer til anvendelse i behandling af kræft
TW201828932A (zh) 2016-11-09 2018-08-16 美商諾沃麥迪斯有限責任公司 1,1-二甲基雙胍之亞硝酸鹽、醫藥組合物及使用方法
WO2018089692A1 (fr) 2016-11-09 2018-05-17 Phloronol, Inc. Dérivés d'eckol, procédés de synthèse et utilisations associées
CN110191705A (zh) 2016-12-01 2019-08-30 亚尼塔公司 治疗癌症的方法
WO2018102673A1 (fr) 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Utilisation de valbénazine pour le traitement de la schizophrénie ou d'un trouble schizo-affectif
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
KR20230038601A (ko) 2017-01-27 2023-03-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 ｖｍａｔ2 억제제의 투여 방법
EP3432883B1 (fr) 2017-02-21 2021-07-28 Kura Oncology, Inc. Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2018164996A1 (fr) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Posologie pour la valbénazine
US11555031B2 (en) 2017-03-20 2023-01-17 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
CN110799192A (zh) 2017-03-27 2020-02-14 加利福尼亚大学董事会 治疗癌症的组合物和方法
JP2020515611A (ja) 2017-03-29 2020-05-28 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３−修飾サキシトキシン
EP3601291A1 (fr) 2017-03-29 2020-02-05 Siteone Therapeutics, Inc. Saxitoxines 11,13-modifiées destinées au traitement de la douleur
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
US11161845B2 (en) 2017-05-19 2021-11-02 Nflection Therapeutics, Inc. Pyrrolopyridine-aniline compounds for treatment of dermal disorders
CN111093658B (zh) 2017-05-19 2022-10-14 恩福莱克逊治疗有限公司 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物
JP2020522504A (ja) 2017-06-01 2020-07-30 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ 多環式化合物およびそれらの用途
MY200746A (en) 2017-08-07 2024-01-13 Kura Oncology Inc Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CA3076000A1 (fr) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. Formulation de valbenazine a dosage eleve et compositions, procedes et kits associes
EP3691658A4 (fr) 2017-10-04 2021-06-23 The Regents of The University of California Oligosaccharides immunomodulateurs
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
WO2019113269A1 (fr) 2017-12-08 2019-06-13 Kura Oncology, Inc. Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
TWI823890B (zh) 2018-01-10 2023-12-01 美商克拉治療有限責任公司 包含苯基磺醯胺之醫藥組合物及其治療應用
US20210052529A1 (en) 2018-01-10 2021-02-25 Cura Therapeutics, Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
KR20210021006A (ko) 2018-06-14 2021-02-24 뉴로크린 바이오사이언시즈 인코퍼레이티드 Vmat2 억제제 화합물, 조성물 및 그와 관련된 방법
CA3105352A1 (fr) 2018-06-29 2020-01-02 Histogen, Inc. Derives d'acide (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoique et composes apparentes utilises en tant qu'inhibiteurs de caspase pour le traitement de maladies cardiovasculaires
EP3836926A4 (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. Procédés d'administration de certains inhibiteurs de vmat2
EP3860714B1 (fr) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. Saxitoxines 11,13-modifiées destinées au traitement de la douleur
CA3117968A1 (fr) 2018-11-01 2020-05-07 Kura Oncology, Inc. Methodes de traitement du cancer avec des inhibiteurs de la farnesyltransferase
JP2022511127A (ja) 2018-11-20 2022-01-28 エヌフレクション セラピューティクス インコーポレイテッド あざの処置のためのアリールアニリンおよびヘテロアリールアニリン化合物
EP4233865A3 (fr) 2018-11-20 2023-09-27 NFlection Therapeutics, Inc. Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
JP7406264B2 (ja) 2018-11-20 2023-12-27 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのシアノアリール－アニリン化合物
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
CA3124616A1 (fr) 2018-12-21 2020-06-25 Kura Oncology, Inc. Procede de traitement de carcinomes a cellules squameuses
WO2020132700A1 (fr) 2018-12-21 2020-06-25 Fgh Biotech Inc. Procédés d'utilisation d'inhibiteurs de srebp en combinaison avec du niclosamide et des analogues de celui-ci
WO2020163554A1 (fr) 2019-02-06 2020-08-13 Dice Alpha, Inc. Modulateurs d'il-17a et leurs utilisations
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US11597703B2 (en) 2019-03-07 2023-03-07 Histogen, Inc. Caspase inhibitors and methods of use thereof
WO2020190604A1 (fr) 2019-03-15 2020-09-24 Kura Oncology, Inc. Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
CN113795253A (zh) 2019-03-29 2021-12-14 库拉肿瘤学公司 用法呢基转移酶抑制剂治疗鳞状细胞癌的方法
TW202102218A (zh) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
EP3997068A1 (fr) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Composés de sulfone et leurs compositions pharmaceutiques, et leurs applications thérapeutiques pour le traitement de maladies neurodégénératives
AU2020310190A1 (en) 2019-07-11 2022-02-24 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
EP4003314B1 (fr) 2019-07-26 2024-07-10 Espervita Therapeutics, Inc. Acides monocarboxyliques et dicarboxyliques d'hydrocarbure à chaîne longue fonctionnalisés utiles pour la prévention ou le traitement d'une maladie
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
KR20220101075A (ko) 2019-09-16 2022-07-19 다이스 알파, 인크. Il-17a 조절인자 및 이의 용도
US20230008367A1 (en) 2019-09-26 2023-01-12 Abionyx Pharma Sa Compounds useful for treating liver diseases
TW202126631A (zh) 2019-10-01 2021-07-16 美商分子皮膚療法公司 作為klk5/7雙重抑制劑之苯并酮化合物
US11529331B2 (en) 2020-05-29 2022-12-20 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
WO2021257828A1 (fr) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Thiénopyrimidines qui interagissent avec la superfamille ras pour le traitement de cancers, de maladies inflammatoires, de rasopathies et d'une maladie fibreuse
WO2022006228A1 (fr) 2020-06-30 2022-01-06 Prosetta Biosciences, Inc. Dérivés d'isoquinoléine, leurs procédés de synthèse et leurs utilisations
AU2021326546A1 (en) 2020-08-14 2023-04-13 Siteone Therapeutics, Inc. Non-hydrated ketone inhibitors of NaV1.7 for the treatment of pain
WO2022164997A1 (fr) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Méthodes pour le traitement d'une maladie fibrotique
WO2022165000A1 (fr) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Méthodes pour le traitement d'une maladie fibrotique
WO2022189856A1 (fr) 2021-03-08 2022-09-15 Abionyx Pharma Sa Composés utiles pour le traitement des maladies du foie
CR20230472A (es) 2021-03-10 2024-03-21 Dice Molecules Sv Inc Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
EP4326721A1 (fr) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Imidazolidinediones et imidazolidinones spirocycliques pour le traitement d'une amylose à chaîne légère
EP4347568A1 (fr) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Hétéroaryl-diamides activateurs d'ire1/xbp1s
WO2023069770A1 (fr) 2021-10-22 2023-04-27 Prosetta Biosciences, Inc. Nouveaux agents thérapeutiques antiviraux pan-respiratoires à petites molécules ciblant l'hôte
WO2023102378A1 (fr) 2021-11-30 2023-06-08 Kura Oncology, Inc. Composés macrocycliques ayant une activité inhibitrice de la farnésyltransférase
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
WO2023129576A2 (fr) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Promedicaments thiol acycliques
TW202400593A (zh) 2022-03-28 2024-01-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ家族離胺酸乙醯轉移酶之抑制劑
WO2023192904A1 (fr) 2022-03-30 2023-10-05 Biomarin Pharmaceutical Inc. Oligonucléotides de saut d'exon de dystrophine
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
WO2023201282A1 (fr) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Nouveaux composés gspt1 et procédés d'utilisation des nouveaux composés
WO2023201348A1 (fr) 2022-04-15 2023-10-19 Celgene Corporation Procédés de prédiction de la réactivité d'un lymphome à un médicament et méthodes de traitement du lymphome
WO2023211990A1 (fr) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Inhibiteurs d'amides hétérocycliques bicycliques de na v1.8 pour le traitement de la douleur
WO2023215781A1 (fr) 2022-05-05 2023-11-09 Biomarin Pharmaceutical Inc. Méthode de traitement de la dystrophie musculaire de duchenne
WO2024054832A1 (fr) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. COMPOSÉS DE DÉGRADATION CK1α ET DOUBLE CK1α/GSPT1
US20240131005A1 (en) 2022-09-30 2024-04-25 Boulder Bioscience Llc Compositions and methods for treating non-hemorrhagic closed head injury
WO2024086246A2 (fr) 2022-10-18 2024-04-25 Eluciderm Inc. 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3-djpyrimidin-4-ones substituées en position 2 pour le traitement des plaies
WO2024092040A1 (fr) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Composés hétéroaryle bicycliques contenant un spirocycle
WO2024092043A1 (fr) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Composés de pyridine contenant un spirocycle
US20240174672A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridone Compounds
WO2024118801A1 (fr) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Diamides hétéroaryles linéaires comme activateurs d'ire1/xbp1s
WO2024118810A1 (fr) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Activateurs de ire1/xbp1 diamide de pyrazole cyclique
WO2024145662A1 (fr) 2022-12-30 2024-07-04 Altay Therapeutics, Inc. Compositions de thiazole et de benzothiazole 2-substituées en tant qi'inhibiteurs de dux4 et procédés

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US110904A (en) * 1871-01-10 Improvement in looms
US1995970A (en) 1931-04-04 1935-03-26 Du Pont Polymeric lactide resin
US2362511A (en) 1939-11-21 1944-11-14 Du Pont Modified glycolide resins
US2438208A (en) 1943-07-10 1948-03-23 Us Agriculture Continuous process of converting lactic acid to polylactic acid
US2703316A (en) 1951-06-05 1955-03-01 Du Pont Polymers of high melting lactide
US2758987A (en) 1952-06-05 1956-08-14 Du Pont Optically active homopolymers containing but one antipodal species of an alpha-monohydroxy monocarboxylic acid
US3043782A (en) 1958-12-22 1962-07-10 Upjohn Co Process for preparing a more impermeable coating by liquid-liquid phase separation
GB929402A (en) 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
US3092553A (en) 1959-01-30 1963-06-04 Jr Carl E Fisher Pharmaceutical preparations and method and apparatus for making same
GB1298194A (en) 1968-11-20 1972-11-29 Agfa Gevaert Improved method for encapsulating aqueous or hydrophilic material, the capsules obtained therewith and their application
BE634668A (fr) 1962-07-11
US3297033A (en) 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3565956A (en) * 1964-10-16 1971-02-23 Sterling Drug Inc Amino-lower-alkoxy-5-alkylidene-dibenzo(a,d)cycloheptenes
JPS433017Y1 (fr) 1964-12-28 1968-02-07
US3755553A (en) 1968-04-18 1973-08-28 S Kutolin Method of producing salts of alkaline earth metals
US3539465A (en) 1968-10-08 1970-11-10 Ncr Co Encapsulation of hydrophilic liquid-in-oil emulsions
US3565869A (en) 1968-12-23 1971-02-23 American Cyanamid Co Extrudable and stretchable polyglycolic acid and process for preparing same
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3703576A (en) 1969-08-08 1972-11-21 Fuji Photo Film Co Ltd Method of producing micro-capsules enclosing acetylsalicylic acid therein
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE759520A (fr) 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions d'aspirine
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
BE758156R (fr) 1970-05-13 1971-04-28 Ethicon Inc Element de suture absorbable et sa
US3705576A (en) * 1970-09-25 1972-12-12 Research Corp Incubators for infants
US3755558A (en) 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en) 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
BE792550A (nl) 1971-12-23 1973-06-12 Agfa Gevaert Nv Procede voor het vervaardigen van microcapsules
JPS5210427B2 (fr) 1972-07-19 1977-03-24
US3818250A (en) 1973-02-07 1974-06-18 Motorola Inc Bistable multivibrator circuit
US3912692A (en) 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3890283A (en) 1973-06-04 1975-06-17 American Cyanamid Co Process for post-polymerizing polyglycolic acid
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
FR2236483B1 (fr) 1973-07-12 1976-11-12 Choay Sa
US4066568A (en) 1975-08-07 1978-01-03 Nippon Pulp Industry Company Limited Method of producing microcapsules
US4137921A (en) 1977-06-24 1979-02-06 Ethicon, Inc. Addition copolymers of lactide and glycolide and method of preparation
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4585651A (en) 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
JPS55114193A (en) 1979-02-26 1980-09-03 Hitachi Ltd Current-supplying device for brushless motor
US4234571A (en) 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4249531A (en) 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
DE2930248A1 (de) 1979-07-26 1981-02-12 Bayer Ag Verfahren zur herstellung von mikrokapseln
US4622244A (en) 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4273920A (en) 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
US4933105A (en) 1980-06-13 1990-06-12 Sandoz Pharm. Corp. Process for preparation of microspheres
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4341767A (en) * 1980-10-06 1982-07-27 Syntex Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4479911A (en) 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4637905A (en) 1982-03-04 1987-01-20 Batelle Development Corporation Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4542025A (en) 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4605730A (en) 1982-10-01 1986-08-12 Ethicon, Inc. Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4523591A (en) 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4555399A (en) 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
CA1256638A (fr) 1984-07-06 1989-06-27 Motoaki Tanaka Polymere, et sa production
JPH0678425B2 (ja) * 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
US4612364A (en) 1984-10-05 1986-09-16 Takeda Chemical Industries Method for producing formed product of high molecular compounds
US4690916A (en) * 1984-11-13 1987-09-01 Syntex (U.S.A.) Inc. Nona and decapeptide analogs of LHRH useful as LHRH antagonists
US4667191A (en) * 1984-12-21 1987-05-19 Motorola, Inc. Serial link communications protocol
ATE61935T1 (de) 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
GB8609537D0 (en) * 1986-04-18 1986-05-21 Ici Plc Polyesters
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
JPH0725689B2 (ja) 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
DE3710175A1 (de) * 1987-02-12 1988-08-25 Hoechst Ag Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung
JPS63218632A (ja) * 1987-03-06 1988-09-12 Japan Atom Energy Res Inst ホルモンに徐放性機能を付与した生体分解型コポリ（グルコ−ル酸／ｌ−乳酸）複合体の製造方法
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
CA1334379C (fr) 1987-11-24 1995-02-14 James William Mcginity Methode de preparation d'une composition active a liberation prolongee
US5110904A (en) * 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
US5036047A (en) * 1988-09-29 1991-07-30 Pitman-Moore, Inc. Method and composition for preventing conception
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JP3116311B2 (ja) * 1990-06-13 2000-12-11 エーザイ株式会社 マイクロスフィアの製法
CA2046830C (fr) * 1990-07-19 1999-12-14 Patrick P. Deluca Systeme d'administration des medicaments comprenant une interaction entre une proteine ou une polypeptide et un polymere hydrophobe biodegradable
GB2246514B (en) 1990-08-01 1993-12-15 Scras Sustained release pharmaceutical compositions and the preparation of particles for use therein
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
CA2143044C (fr) * 1994-02-21 2005-04-12 Yasutaka Igari Matrice pour preparation a degagement prolonge
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process

Also Published As

Publication number Publication date
DE69330547D1 (de) 2001-09-13
DE69333817T2 (de) 2006-02-02
CN100488560C (zh) 2009-05-20
TW333456B (en) 1998-06-11
AU5211393A (en) 1994-06-16
LV10927A (lv) 1995-12-20
MX9307686A (es) 1994-06-30
DE69333817D1 (de) 2005-06-23
PT601799E (pt) 2001-12-28
US6528093B1 (en) 2003-03-04
DE69330547T2 (de) 2001-11-22
EP0601799B1 (fr) 2001-08-08
EP1088555B1 (fr) 2005-05-18
US5972891A (en) 1999-10-26
LV10927B (en) 1996-04-20
US5668111A (en) 1997-09-16
KR20010016379A (ko) 2001-03-05
NO934423L (no) 1994-06-08
GR3037085T3 (en) 2002-01-31
EP1088555A1 (fr) 2001-04-04
US7048947B2 (en) 2006-05-23
PT1088555E (pt) 2005-07-29
US20020173467A1 (en) 2002-11-21
GEP19991600B (en) 1999-04-29
CN1096221A (zh) 1994-12-14
KR100319425B1 (ko) 2002-01-09
ATE203910T1 (de) 2001-08-15
JPH0797334A (ja) 1995-04-11
CN1428144A (zh) 2003-07-09
DK0601799T3 (da) 2001-10-01
SG46283A1 (en) 1998-02-20
CA2110730A1 (fr) 1994-06-08
NO934423D0 (no) 1993-12-06
US5480868A (en) 1996-01-02
US20030039698A1 (en) 2003-02-27
NZ250349A (en) 1994-12-22
CA2110730C (fr) 2008-09-16
DK1088555T3 (da) 2005-07-04
WO1994013317A1 (fr) 1994-06-23
FI116196B (fi) 2005-10-14
ES2158856T3 (es) 2001-09-16
JP3725906B2 (ja) 2005-12-14
FI20030166A (fi) 2003-02-04
NO310704B1 (no) 2001-08-20
FI935471A0 (fi) 1993-12-07
CN1099893C (zh) 2003-01-29
ES2238247T3 (es) 2005-09-01
KR100305951B1 (ko) 2001-11-30
AU669939B2 (en) 1996-06-27
HK1037519A1 (en) 2002-02-15
EE03117B1 (et) 1998-10-15
EP0601799A1 (fr) 1994-06-15
KR940013530A (ko) 1994-07-15
US20090048180A1 (en) 2009-02-19
ATE295733T1 (de) 2005-06-15
US20020147150A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
FI935471A (fi) Pysyvästi vapauttava valmiste
ATE159945T1 (de) Beta-aminoalkyl und beta-n- peptidylaminoalkylborsäure
FI915282A0 (fi) Mono-n-substituerade 1,4,7,10-tetra -azacyklododekanderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska aemnen.
NO911854L (no) Fremgangsmaate for fremstilling av peptid-derivater.
ATE188472T1 (de) 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
DE3784799D1 (de) Malonsaeurederivate und ihre synthesemethoden.
FI920340A (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara somatostatinderivat.
HUT64842A (en) Method for producing pharmaceutical preparatives containing 2-[n-(2-amino-ethyl)-amino]-acetic acid derivatives
MY112411A (en) Indole derivatives.
DE69017180D1 (de) Biologisch wirksame polymere arzneistoffderivate.
CO5150192A1 (es) Nuevos antagonistas de la lhrh que contienen componentes de aminoacido n-metilados con propiedades mejoradas de solubilidad
PE20001241A1 (es) Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
DE69224613D1 (de) Peptide, Herstellung und deren Verwendung
CA2251060A1 (fr) Promedicaments acyles de la n-hydroxymethylthalidomide a effet immunomodulateur
TH13519A (th) อนุพันธ์อินโดล
TH13519EX (th) อนุพันธ์อินโดล